Sepsis and septic shock

The Lancet

Volumn 392, Issue 10141, 2018, Pages 75-87

  Cecconi, Maurizio ^a   Evans, Laura ^b   Levy, Mitchell ^c   Rhodes, Andrew ^d  

^a HUMANITAS UNIVERSITY   (Italy)

^b BELLEVUE HOSPITAL CENTER   (United States)

^c BROWN UNIVERSITY   (United States)

^d ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; DROTRECOGIN; FLUDROCORTISONE; HYDROCORTISONE; METHYLPREDNISOLONE; NORADRENALIN; SELEPRESSIN; THROMBOMODULIN; VASOPRESSIN;

ARTERIAL OXYGEN SATURATION; BACTERIAL INFECTION; ESCHERICHIA COLI; FLUID RESUSCITATION; HUMAN; ICD-9; INCIDENCE; INFECTION RISK; LACTATE BLOOD LEVEL; NONHUMAN; NUTRITIONAL SUPPORT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSEUDOMONAS; REVIEW; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; STAPHYLOCOCCUS AUREUS; SYSTEMATIC REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOTAL QUALITY MANAGEMENT; TREATMENT OUTCOME; MEDICAL RESEARCH; MORTALITY; ORGAN DYSFUNCTION SCORE; PERSONALIZED MEDICINE; SEPSIS; SURVIVAL RATE;

BIOMEDICAL RESEARCH; HUMANS; ORGAN DYSFUNCTION SCORES; PRECISION MEDICINE; SEPSIS; SHOCK, SEPTIC; SURVIVAL RATE;

EID: 85048709962     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(18)30696-2     Document Type: Review

References (148)

1. Fleischmann, C, Scherag, A, Adhikari, NK, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med 193 (2016), 259–272.
2. Tiru, B, DiNino, EK, Orenstein, A, et al. The economic and humanistic burden of severe sepsis. Pharmacoeconomics 33 (2015), 925–937.
3. Singer, M, Deutschman, CS, Seymour, CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 (2016), 801–810.
4. Reinhart, K, Daniels, R, Kissoon, N, Machado, FR, Schachter, RD, Finfer, S, Recognizing sepsis as a global health priority—a WHO resolution. N Engl J Med 377 (2017), 414–417.
5. Vincent, JL, Moreno, R, Takala, J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22 (1996), 707–710.
6. Bone, RC, Fisher, CJ Jr, Clemmer, TP, Slotman, GJ, Metz, CA, Balk, RA, Sepsis syndrome: a valid clinical entity. Crit Care Med 17 (1989), 389–393.
7. Bone, RC, Balk, RA, Cerra, FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101 (1992), 1644–1655.
8. Levy, MM, Fink, MP, Marshall, JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29 (2003), 530–538.
9. Shankar-Hari, M, Phillips, GS, Levy, ML, et al. Developing a new definition and assessing new clinical criteria for septic shock: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 (2016), 775–787.
10. Seymour, CW, Liu, VX, Iwashyna, TJ, et al. Assessment of clinical criteria for sepsis: for the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 315 (2016), 762–774.
11. Churpek, MM, Snyder, A, Han, X, et al. Quick sepsis-related organ failure assessment, systemic inflammatory response syndrome, and early warning scores for detecting clinical deterioration in infected patients outside the intensive care unit. Am J Respir Crit Care Med 195 (2017), 906–911.
12. Adhikari, NK, Fowler, RA, Bhagwanjee, S, Rubenfeld, GD, Critical care and the global burden of critical illness in adults. Lancet 376 (2010), 1339–1346.
13. Angus, DC, Linde-Zwirble, WT, Lidicker, J, Clermont, G, Carcillo, J, Pinsky, MR, Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29 (2001), 1303–1310.
14. Mayr, FB, Yende, S, Angus, DC, Epidemiology of severe sepsis. Virulence 5 (2014), 4–11.
15. Rhodes, A, Ferdinande, P, Flaatten, H, Guidet, B, Metnitz, PG, Moreno, RP, The variability of critical care bed numbers in Europe. Intensive Care Med 38 (2012), 1647–1653.
16. Levy, MM, Artigas, A, Phillips, GS, et al. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis 12 (2012), 919–924.
17. Liu, V, Escobar, GJ, Greene, JD, et al. Hospital deaths in patients with sepsis from 2 independent cohorts. JAMA 312 (2014), 90–92.
18. Black, RE, Cousens, S, Johnson, HL, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375 (2010), 1969–1987.
19. Flaatten, H, De Lange, DW, Morandi, A, et al. The impact of frailty on ICU and 30-day mortality and the level of care in very elderly patients (≥ 80 years). Intensive Care Med 43 (2017), 1820–1828.
20. Vincent, JL, Rello, J, Marshall, J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 302 (2009), 2323–2329.
21. Vincent, JL, Sakr, Y, Sprung, CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34 (2006), 344–353.
22. Karlsson, S, Varpula, M, Ruokonen, E, et al. Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. Intensive Care Med 33 (2007), 435–443.
23. Martin, GS, Mannino, DM, Eaton, S, Moss, M, The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348 (2003), 1546–1554.
24. Vincent, JL, Marshall, JC, Namendys-Silva, SA, et al. Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit. Lancet Respir Med 2 (2014), 380–386.
25. Vincent, JL, Lefrant, JY, Kotfis, K, et al. Comparison of European ICU patients in 2012 (ICON) versus 2002 (SOAP). Intensive Care Med, 2018, 10.1007/s00134-017-5043-2 published online Feb 15.
26. Boyd, JH, Russell, JA, Fjell, CD, The meta-genome of sepsis: host genetics, pathogens and the acute immune response. J Innate Immun 6 (2014), 272–283.
27. Hotchkiss, RS, Karl, IE, The pathophysiology and treatment of sepsis. N Engl J Med 348 (2003), 138–150.
28. Hotchkiss, RS, Monneret, G, Payen, D, Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 13 (2013), 862–874.
29. Hotchkiss, RS, Opal, S, Immunotherapy for sepsis—a new approach against an ancient foe. N Engl J Med 363 (2010), 87–89.
30. Vincent, JL, Zhang, H, Szabo, C, Preiser, JC, Effects of nitric oxide in septic shock. Am J Respir Crit Care Med 161 (2000), 1781–1785.
31. Carsetti, A, Aya, HD, Pierantozzi, S, et al. Ability and efficiency of an automatic analysis software to measure microvascular parameters. J Clin Monit Comput 31 (2016), 669–676.
32. Bezemer, R, Bartels, SA, Bakker, J, Ince, C, Clinical review: Clinical imaging of the sublingual microcirculation in the critically ill—where do we stand?. Crit Care, 16, 2012, 224.
33. Buwalda, M, Ince, C, OPening the microcirculation: can vasodilators be useful in sepsis?. Intensive Care Med 28 (2002), 1208–1217.
34. McGown, CC, Brown, NJ, Hellewell, PG, Brookes, ZL, ROCK induced inflammation of the microcirculation during endotoxemia mediated by nitric oxide synthase. Microvasc Res 81 (2011), 281–288.
35. Singer, M, The role of mitochondrial dysfunction in sepsis-induced multi-organ failure. Virulence 5 (2014), 66–72.
36. Dellinger, RP, Levy, MM, Rhodes, A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39 (2013), 165–228.
37. Simmons, J, Pittet, JF, The coagulopathy of acute sepsis. Curr Opin Anaesthesiol 28 (2015), 227–236.
38. Vincent, JL, Bihari, DJ, Suter, PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 274 (1995), 639–644.
39. Williams, PT, Inadequate exercise as a risk factor for sepsis mortality. PLoS One, 8, 2013, e79344.
40. O'Keefe, GE, Hybki, DL, Munford, RS, The G—>A single nucleotide polymorphism at the −308 position in the tumor necrosis factor-alpha promoter increases the risk for severe sepsis after trauma. J Trauma 52 (2002), 817–825.
41. Tang, GJ, Huang, SL, Yien, HW, et al. Tumor necrosis factor gene polymorphism and septic shock in surgical infection. Crit Care Med 28 (2000), 2733–2736.
42. Thompson, CM, Holden, TD, Rona, G, et al. Toll-like receptor 1 polymorphisms and associated outcomes in sepsis after traumatic injury: a candidate gene association study. Ann Surg 259 (2014), 179–185.
43. Waterer, GW, Quasney, MW, Cantor, RM, Wunderink, RG, Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 163 (2001), 1599–1604.
44. Kaukonen, KM, Bailey, M, Pilcher, D, Cooper, DJ, Bellomo, R, Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med 372 (2015), 1629–1638.
45. Levy, MM, Dellinger, RP, Townsend, SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Crit Care Med 38 (2010), 367–374.
46. Dellinger, RP, Levy, MM, Carlet, JM, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36 (2008), 296–327.
47. Hollenberg, SM, Ahrens, TS, Annane, D, et al. Practice parameters for hemodynamic support of sepsis in adult patients: 2004 update. Crit Care Med 32 (2004), 1928–1948.
48. Weinstein, MP, Reller, LB, Murphy, JR, Lichtenstein, KA, The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. Rev Infect Dis 5 (1983), 35–53.
49. Rivers, E, Nguyen, B, Havstad, S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345 (2001), 1368–1377.
50. Davis, AL, Carcillo, JA, Aneja, RK, et al. American College of Critical Care Medicine clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock. Crit Care Med 45 (2017), 1061–1093.
51. Maitland, K, Kiguli, S, Opoka, RO, et al. Mortality after fluid bolus in African children with severe infection. N Engl J Med 364 (2011), 2483–2495.
52. Andrews, B, Semler, MW, Muchemwa, L, et al. Effect of an early resuscitation protocol on in-hospital mortality among adults with sepsis and hypotension: a randomized clinical trial. JAMA 318 (2017), 1233–1240.
53. Caironi, P, Tognoni, G, Masson, S, et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med 370 (2014), 1412–1421.
54. Finfer, S, Bellomo, R, Boyce, N, French, J, Myburgh, J, Norton, R, A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 350 (2004), 2247–2256.
55. Perner, A, Haase, N, Guttormsen, AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 367 (2012), 124–134.
56. Myburgh, JA, Finfer, S, Bellomo, R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 367 (2012), 1901–1911.
57. Yunos, NM, Bellomo, R, Hegarty, C, Story, D, Ho, L, Bailey, M, Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 308 (2012), 1566–1572.
58. Semler, MW, Self, WH, Wanderer, JP, et al. Balanced crystalloids versus saline in critically ill adults. N Engl J Med 378 (2018), 829–839.
59. Hammond, NE, Bellomo, R, Gallagher, M, et al. The Plasma-Lyte 148 v Saline (PLUS) study protocol: a multicentre, randomised controlled trial of the effect of intensive care fluid therapy on mortality. Crit Care Resusc 19 (2017), 239–246.
60. Zampieri, FG, Azevedo, LCP, Corrêa, TD, et al. Study protocol for the Balanced Solution versus Saline in Intensive Care Study (BaSICS): a factorial randomised trial. Crit Care Resusc 19 (2017), 175–182.
61. Marshall, JC, Maier, RV, Jimenez, M, Dellinger, EP, Source control in the management of severe sepsis and septic shock: an evidence-based review. Crit Care Med 32:11 suppl (2004), S513–S526.
62. Garnacho-Montero, J, Ortiz-Leyba, C, Herrera-Melero, I, et al. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study. J Antimicrob Chemother 61 (2008), 436–441.
63. Kumar, A, Roberts, D, Wood, KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34 (2006), 1589–1596.
64. Ferrer, R, Martin-Loeches, I, Phillips, G, et al. Empiric antibiotic treatment reduces mortality in severe sepsis and septic shock from the first hour: results from a guideline-based performance improvement program. Crit Care Med 42 (2014), 1749–1755.
65. Seymour, CW, Gesten, F, Prescott, HC, et al. Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 376 (2017), 2235–2244.
66. Wright, J, Paauw, DS, Complications of antibiotic therapy. Med Clin North Am 97 (2013), 667–679 xi.
67. Singh, R, Sripada, L, Singh, R, Side effects of antibiotics during bacterial infection: mitochondria, the main target in host cell. Mitochondrion 16 (2014), 50–54.
68. Singer, M, Antibiotics for sepsis: does each hour really count, or is it incestuous amplification?. Am J Respir Crit Care Med 196 (2017), 800–802.
69. Ibrahim, EH, Sherman, G, Ward, S, Fraser, VJ, Kollef, MH, The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 (2000), 146–155.
70. Rhodes, A, Evans, LE, Alhazzani, W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Crit Care Med 45 (2017), 486–552.
71. Roca, I, Akova, M, Baquero, F, et al. The global threat of antimicrobial resistance: science for intervention. New Microbes New Infect 6 (2015), 22–29.
72. Marik, PE, Monnet, X, Teboul, JL, Hemodynamic parameters to guide fluid therapy. Ann Intensive Care, 1, 2011, 1.
73. Pinsky, MR, Payen, D, Functional hemodynamic monitoring. Crit Care 9 (2005), 566–572.
74. Vincent, JL, Weil, MH, Fluid challenge revisited. Crit Care Med 34 (2006), 1333–1337.
75. Cavallaro, F, Sandroni, C, Antonelli, M, Functional hemodynamic monitoring and dynamic indices of fluid responsiveness. Minerva Anestesiol 74 (2008), 123–135.
76. Cavallaro, F, Sandroni, C, Marano, C, et al. Diagnostic accuracy of passive leg raising for prediction of fluid responsiveness in adults: systematic review and meta-analysis of clinical studies. Intensive Care Med 36 (2010), 1475–1483.
77. Guerin, L, Monnet, X, Teboul, JL, Monitoring volume and fluid responsiveness: from static to dynamic indicators. Best Pract Res Clin Anaesthesiol 27 (2013), 177–185.
78. Teboul, JL, Monnet, X, Prediction of volume responsiveness in critically ill patients with spontaneous breathing activity. Curr Opin Crit Care 14 (2008), 334–339.
79. Hoste, EA, Maitland, K, Brudney, CS, et al. Four phases of intravenous fluid therapy: a conceptual model. Br J Anaesth 113 (2014), 740–747.
80. Mouncey, PR, Osborn, TM, Power, GS, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 372 (2015), 1301–1311.
81. Yealy, DM, Kellum, JA, Huang, DT, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med 370 (2014), 1683–1693.
82. Peake, SL, Delaney, A, Bailey, M, Goal-directed resuscitation for patients with early septic shock. N Engl J Med 371 (2014), 1496–1506.
83. Rowan, KM, Angus, DC, Bailey, M, et al. Early, goal-directed therapy for septic shock—a patient-level meta-analysis. N Engl J Med 376 (2017), 2223–2234.
84. Gu, WJ, Zhang, Z, Bakker, J, Early lactate clearance-guided therapy in patients with sepsis: a meta-analysis with trial sequential analysis of randomized controlled trials. Intensive Care Med 41 (2015), 1862–1863.
85. Jansen, TC, van Bommel, J, Schoonderbeek, FJ, et al. Early lactate-guided therapy in intensive care unit patients: a multicenter, open-label, randomized controlled trial. Am J Respir Crit Care Med 182 (2010), 752–761.
86. Jones, AE, Shapiro, NI, Trzeciak, S, et al. Lactate clearance vs central venous oxygen saturation as goals of early sepsis therapy: a randomized clinical trial. JAMA 303 (2010), 739–746.
87. Casserly, B, Phillips, GS, Schorr, C, et al. Lactate measurements in sepsis-induced tissue hypoperfusion: results from the Surviving Sepsis Campaign database. Crit Care Med 43 (2015), 567–573.
88. Cecconi, M, De Backer, D, Antonelli, M, et al. Consensus on circulatory shock and hemodynamic monitoring. Task force of the European Society of Intensive Care Medicine. Intensive Care Med 40 (2014), 1795–1815.
89. Asfar, P, Meziani, F, Hamel, JF, et al. High versus low blood-pressure target in patients with septic shock. N Engl J Med 370 (2014), 1583–1593.
90. De Backer, D, Biston, P, Devriendt, J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362 (2010), 779–789.
91. De Backer, D, Creteur, J, Silva, E, Vincent, JL, Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best?. Crit Care Med 31 (2003), 1659–1667.
92. Martin, C, Papazian, L, Perrin, G, Saux, P, Gouin, F, Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?. Chest 103 (1993), 1826–1831.
93. Dunser, MW, Mayr, AJ, Ulmer, H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 107 (2003), 2313–2319.
94. Holmes, CL, Walley, KR, Chittock, DR, Lehman, T, Russell, JA, The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 27 (2001), 1416–1421.
95. Landry, DW, Levin, HR, Gallant, EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 95 (1997), 1122–1125.
96. Russell, JA, Walley, KR, Singer, J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358 (2008), 877–887.
97. Gordon, AC, Mason, AJ, Thirunavukkarasu, N, et al. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 316 (2016), 509–518.
98. Russell, JA, Vincent, J-L, Kjølbye, AL, et al. Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients. Crit Care, 21, 2017, 213.
99. Khanna, A, English, SW, Wang, XS, et al. Angiotensin II for the treatment of vasodilatory shock. N Engl J Med 377 (2017), 419–430.
100. Heming, N, Lamothe, L, Ambrosi, X, Annane, D, Emerging drugs for the treatment of sepsis. Expert Opin Emerg Drugs 21 (2016), 27–37.
101. He, X, Su, F, Taccone, FS, Laporte, R, Kjølbye, AL, Zhang, J, A selective V(1A) receptor agonist, selepressin, is superior to arginine vasopressin and to norepinephrine in ovine septic shock. Crit Care Med 44 (2016), 23–31.
102. Asfar, P, Russell, JA, Tuckermann, J, Radermacher, P, Selepressin in septic shock: a step toward decatecholaminization?. Crit Care Med 44 (2016), 234–236.
103. Kakihana, Y, Ito, T, Nakahara, M, Yamaguchi, K, Yasuda, T, Sepsis-induced myocardial dysfunction: pathophysiology and management. J Intensive Care, 4, 2016, 22.
104. Vieillard-Baron, A, Cecconi, M, Understanding cardiac failure in sepsis. Intensive Care Med 40 (2014), 1560–1563.
105. Parker, MM, Shelhamer, JH, Bacharach, SL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100 (1984), 483–490.
106. Sanfilippo, F, Corredor, C, Fletcher, N, et al. Diastolic dysfunction and mortality in septic patients: a systematic review and meta-analysis. Intensive Care Med 41 (2015), 1004–1013.
107. Vieillard-Baron, A, Caille, V, Charron, C, Belliard, G, Page, B, Jardin, F, Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med 36 (2008), 1701–1706.
108. Gordon, AC, Perkins, GD, Singer, M, et al. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med 375 (2016), 1638–1648.
109. Van den Berghe, G, Wouters, P, Weekers, F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 345 (2001), 1359–1367.
110. Van den Berghe, G, Wilmer, A, Hermans, G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 354 (2006), 449–461.
111. Finfer, S, Chittock, DR, Su, SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 360 (2009), 1283–1297.
112. Harvey, SE, Parrott, F, Harrison, DA, et al. A multicentre, randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of early nutritional support via the parenteral versus the enteral route in critically ill patients (CALORIES). Health Technol Assess 20 (2016), 1–144.
113. Reignier, J, Boisramé-Helms, J, Brisard, L, et al. Enteral versus parenteral early nutrition in ventilated adults with shock: a randomised, controlled, multicentre, open-label, parallel-group study (NUTRIREA-2). Lancet 391 (2018), 133–143.
114. Annane, D, Sébille, V, Charpentier, C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288 (2002), 862–871.
115. Sprung, CL, Annane, D, Keh, D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 358 (2008), 111–124.
116. Gibbison, B, López-López, JA, Higgins, JP, et al. Corticosteroids in septic shock: a systematic review and network meta-analysis. Crit Care, 21, 2017, 78.
117. Pastores, SM, Annane, D, Rochwerg, B, Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part II): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017. Intensive Care Med, 2017, 10.1007/s00134-017-4951-5 published online Oct 31.
118. Annane, D, Bellissant, E, Bollaert, PE, Briegel, J, Keh, D, Kupfer, Y, Corticosteroids for treating sepsis. Cochrane Database Syst Rev, 2015, CD002243.
119. Amaya-Villar, R, Garnacho-Montero, J, Garcia-Garmendia, JL, et al. Steroid-induced myopathy in patients intubated due to exacerbation of chronic obstructive pulmonary disease. Intensive Care Med 31 (2005), 157–161.
120. Annane, D, Bellissant, E, Bollaert, PE, et al. Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA 301 (2009), 2362–2375.
121. Sligl, WI, Milner, DA Jr, Sundar, S, Mphatswe, W, Majumdar, SR, Safety and efficacy of corticosteroids for the treatment of septic shock: a systematic review and meta-analysis. Clin Infect Dis 49 (2009), 93–101.
122. Venkatesh, B, Myburgh, J, Finfer, S, et al. The ADRENAL study protocol: adjunctive corticosteroid treatment in critically ill patients with septic shock. Crit Care Resusc 15 (2013), 83–88.
123. Annane, D, Renault, A, Brun-Buisson, C, et al. Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med 378 (2018), 809–818.
124. Hebert, PC, Wells, G, Blajchman, MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 340 (1999), 409–417.
125. Holst, LB, Haase, N, Wetterslev, J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 371 (2014), 1381–1391.
126. Girardis, M, Busani, S, Damiani, E, et al. Effect of conservative vs conventional oxygen therapy on mortality among patients in an intensive care unit: the Oxygen-ICU randomized clinical trial. JAMA 316 (2016), 1583–1589.
127. Asfar, P, Schortgen, F, Boisramé-Helms, J, et al. Hyperoxia and hypertonic saline in patients with septic shock (HYPERS2S): a two-by-two factorial, multicentre, randomised, clinical trial. Lancet Respir Med 5 (2017), 180–190.
128. Ranieri, VM, Thompson, BT, Barie, PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 366 (2012), 2055–2064.
129. Cohen, J, Vincent, JL, Adhikari, NK, et al. Sepsis: a roadmap for future research. Lancet Infect Dis 15 (2015), 581–614.
130. Vincent, JL, Ramesh, MK, Ernest, D, et al. A randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation. Crit Care Med 41 (2013), 2069–2079.
131. Bellingan, G, Maksimow, M, Howell, DC, et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med 2 (2014), 98–107.
132. Wilson, JG, Liu, KD, Zhuo, H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 3 (2015), 24–32.
133. Cruz, DN, Antonelli, M, Fumagalli, R, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301 (2009), 2445–2452.
134. Coudroy, R, Payen, D, Launey, Y, et al. Modulation by polymyxin-B hemoperfusion of inflammatory response related to severe peritonitis. Shock 47 (2017), 93–99.
135. Payen, DM, Guilhot, J, Launey, Y, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 41 (2015), 975–984.
136. Levy, MM, Rhodes, A, Phillips, GS, et al. Surviving Sepsis Campaign: association between performance metrics and outcomes in a 7·5-year study. Intensive Care Med 40 (2014), 1623–1633.
137. Kahn, JM, Benson, NM, Appleby, D, Carson, SS, Iwashyna, TJ, Long-term acute care hospital utilization after critical illness. JAMA 303 (2010), 2253–2259.
138. Jones, TK, Fuchs, BD, Small, DS, et al. Post-acute care use and hospital readmission after sepsis. Ann Am Thorac Soc 12 (2015), 904–913.
139. Liu, V, Lei, X, Prescott, HC, Kipnis, P, Iwashyna, TJ, Escobar, GJ, Hospital readmission and healthcare utilization following sepsis in community settings. J Hosp Med 9 (2014), 502–507.
140. Prescott, HC, Langa, KM, Iwashyna, TJ, Readmission diagnoses after hospitalization for severe sepsis and other acute medical conditions. JAMA 313 (2015), 1055–1057.
141. Wang, T, Derhovanessian, A, De Cruz, S, Belperio, JA, Deng, JC, Hoo, GS, Subsequent infections in survivors of sepsis: epidemiology and outcomes. J Intensive Care Med 29 (2014), 87–95.
142. Iwashyna, TJ, Ely, EW, Smith, DM, Langa, KM, Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 304 (2010), 1787–1794.
143. Winters, BD, Eberlein, M, Leung, J, Needham, DM, Pronovost, PJ, Sevransky, JE, Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 38 (2010), 1276–1283.
144. Battle, CE, Davies, G, Evans, PA, Long term health-related quality of life in survivors of sepsis in South West Wales: an epidemiological study. PLoS One, 9, 2014, e116304.
145. Nesseler, N, Defontaine, A, Launey, Y, Morcet, J, Mallédant, Y, Seguin, P, Long-term mortality and quality of life after septic shock: a follow-up observational study. Intensive Care Med 39 (2013), 881–888.
146. Miller, RR 3rd, Dong, L, Nelson, NC, et al. Multicenter implementation of a severe sepsis and septic shock treatment bundle. Am J Respir Crit Care Med 188 (2013), 77–82.
147. Levy, MM, Evans, LE, Rhodes, A, The Surviving Sepsis Campaign bundle: 2018 update. Intensive Care Med, 2018, 10.1007/s00134-018-5085-0 published online April 19.
148. Kaukonen, KM, Bailey, M, Suzuki, S, Pilcher, D, Bellomo, R, Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 311 (2014), 1308–1316.